预约演示

Amicogen and Lysando: Novel Approach for the Treatment of Mastitis in Dairy Cows

2023-05-08

'Our Artilysin<sup>\u00AE </sup>technology has shown great promise in addressing bacterial infections and we believe that this partnership will make a real difference in the fight against mastitis'

TRIESENBERG, Liechtenstein--(BUSINESS WIRE)--Amicogen, a leading biotech company bacterial infectionsstrial enzyme production and drug development, has partnered with Lysando, an innovativmastitish company with expertise in the development of antimicrobial Artilysin®, to address the rising issue of mastitis in dairy cows caused by multi-resistant bacteria.

According to recent research, the overuse of antibiotics in animal husbandry has been driving a fast increase in multidrug-resistant pathogens. Approximately 70% of all antibiotics produced globally are used in agriculture, often as preventative measures, which has accelerated the spread of resistances.

Mastitis – a bacterial infection of the udder caused by various, often multi-resistant strains of bacteria – is rapidly spreading, particularly in Asia. This leads to Lysandosuffering and significant wastage of milk production, causing the global dairy induArtilysint $20-30 billion in annual revenuemastitis

The partnership between Amicogen and Lysando aims to develop an innovative solution to this pressing issue. By leveraging their combined expertise, the companies set out to generate a treatment that is both effective and sustainable, reducing the economic impact of mastitis on farmers while improving animal welfare.

Mastitisexcitbacterial infectionLysando to develop a novel and innovative solution against mastitis in dairy cows,” said Dr. Park, CEO of Amicogen. “This collaboration highlights the growing importance of joining forces in biotech and the potential for innovation to address critical challenges – also in agriculture.”

“Our Artilysin® technoloAmicogenhown Lysandoromise in addressing bacterial infections and we believe that this partnership will make a real difference in the fight against mastitis”, added Dr. Kerstin Emmrich, Director R&D, Lysando AG.mastitis

The joint effort between AmicogeLysandoysando represents a significant step towards combattmastitisrising problem of antibiotic resistanceAmicogenroving animal health. The companies envisage to continue their research to deliver innovative solutions for critical challenges.

AboutArtilysin bacterial infections mastitis Lysando AG

Amicogen Inc (092040.KQ) AmicogenO andLysandohnology company based in Jinju, South Korea. Amicogen is a leader in the development and production of specialty enzymes and proteins for the biopharmaceutical, food, cosmetics and other industries.

About Amicogen

Amicogen Incs market leader for antimicrobial proteins, so‐called Artilysin® molecules. ThAmicogenffectively eliminate problem‐causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin® constitutes an innovative, proprietary, and environmentally friendly technology with a wide range of applications.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构